ESH Video

7th Translational Research E-Conference: Myelodysplastic Syndromes

7th Translational Research E-Conference: Myelodysplastic Syndromes
January 28 - January 31, 2021 - E-CONFERENCE, #ESHMDS2021
Chairs : Pierre Fenaux, Uwe Platzbecker, Mikkael Sekeres


CONFERENCE UPDATE: novel coronavirus (COVID-19)

November 20, 2020

7th Translational Research E-Conference: Myelodysplastic Syndromes

January 28-31, 2021 – E-CONFERENCE

Chairpersons: Pierre Fenaux, Uwe Platzbecker, Mikkael Sekeres

In view of continuing COVID-19 related challenges and uncertainties, ESH has decided to hold next year’s 7th Translational Research e-Conference on MDS as a virtual event.

An outstanding faculty of distinguished global experts will present the most recent advances and new perspectives in the field of Myelodysplastic Syndromes, from pathophysiology to diagnosis and therapy, including current challenges and new perspectives.

The plenary E-Conference programme is designed to place emphasis on leading-edge basic and clinical research. The presentation of unpublished data is encouraged. Ample time is deliberately provided for scientific discussion and interaction.

Registered participants will further benefit from opportunities for informal scientific interaction with the world’s leading experts in the field during closed Meet the Expert sessions and E-Mentored Posters Walks.

Participants will be joining us from all over the world and from different time zones. To make sure that everyone has access to the full scientific programme at a convenient hour, registration will allow participants to join both the LIVE PROGRAMME and the PROGRAMME ON DEMAND.

– The “Live Programme” is to be found on programme page. It will be streamed live CEST time, as indicated. It will include lectures, Meet the Expert sessions, interactive panel discussions, and Mentored Poster Walks. It will also include some pre-recorded lectures that will be streamed live.

– The “Programme on Demand” available as of January 19, 2021, will initially include the pre-recorded components of the scientific programme. It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.

The Virtual platform will remain open from January 19 until March 2, 2021 so that participants can view and review the programme’s full scientific content at times convenient to them.

We have selected a platform with the technical capacity and environment which we feel responds to ESH objectives in terms of learning, scientific interaction and conviviality.

We hope that you will be interested in joining us for this ESH E-Conference on Myelodysplastic Syndromes,

In the meantime Stay Safe!
The ESH Team





7th Translational Research Conference: Myelodysplastic Syndromes

Chairs: Pierre Fenaux, Uwe Platzbecker, Mikkael Sekeres

Until recently, information on the biology of MDS and options available for its treatment were limited. A lot of data has accumulated in recent years on the pathophysiology of MDS, particularly on the role of somatic mutations (including in very early disease phase), haploinsufficiency for certain genes, and the impact of abnormalities of the microenvironment. Prognostic factors of the disease have also been refined, with the revised IPSS, and new factors like somatic mutations. Treatment approaches are improving, although not at the same speed, and only allogeneic stem cell transplantation remains potentially curative.
The 7th ESH Conference on MDS is designed to provide time and multiple opportunities for critical discussion and informal scientific interaction with internationally recognized experts in the field.

Learning objectives:

  • Learn how to optimally diagnose MDS, mainly by morphological analysis and cytogenetics, but also through the use of new tools, mainly molecular analysis. 

  • Improve ability to analyze prognostic factors, including new ones (revised IPSS, molecular analysis).
  • Review current treatment of MDS, in both the high risk and low risk settings, ranging from single follow up to allogeneic stem cell transplantation.
  • Acquire improved knowledge of emerging treatments, based on targeted therapies and well conducted clinical trials. Diagnostic, prognostic and therapeutic issues will be presented by the faculty and ample time will be devoted to discussion with delegates.


Click here to access the updated scientific programme.          

Abstract submission




Abstracts guidelines:
– Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)
– Maximum number of words: 500
– Your abstract will be submitted to the peer review procedure.

The following file types may be uploaded: HTML document (*.htm), HTML document (*.html), JPEG image (*.jpg), GIF image (*.gif), or PNG image (*.png).




 To visit the E-Conference Platform, click HERE.


Corporate partners

with the support of*

Diamond Conference Partner



Emerald Conference Partner


   Jazz pharma    

Ruby Conference Partners





*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.




Educational Grants

ESH gratefully acknowledges

Celgene-BMS logo

for providing a Medical Education Grant

towards this independent programme.


The registration for the “7th Translational Research E-Conference on Myelodysplastic Syndromes” is free.


Meet the Expert sessions:  Registration fee:  20€
These sessions will be open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats will be available in each session and pre-registration will therefore be required.


Register Here